198 related articles for article (PubMed ID: 29479816)
1. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
Mao Y; Huang X; Shuang Z; Lin G; Wang J; Duan F; Chen J; Li S
Cancer Med; 2018 Apr; 7(4):1285-1296. PubMed ID: 29479816
[TBL] [Abstract][Full Text] [Related]
2. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
Camero S; Ceccarelli S; De Felice F; Marampon F; Mannarino O; Camicia L; Vescarelli E; Pontecorvi P; Pizer B; Shukla R; Schiavetti A; Mollace MG; Pizzuti A; Tombolini V; Marchese C; Megiorni F; Dominici C
J Cancer Res Clin Oncol; 2019 Jan; 145(1):137-152. PubMed ID: 30357520
[TBL] [Abstract][Full Text] [Related]
3. Gemcitabine-Based Chemoradiotherapy Enhanced by a PARP Inhibitor in Pancreatic Cancer Cell Lines.
Waissi W; Amé JC; Mura C; Noël G; Burckel H
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201963
[TBL] [Abstract][Full Text] [Related]
4. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
Liu C; Gross N; Li Y; Li G; Wang Z; Zhong S; Li Y; Hu G
J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
[TBL] [Abstract][Full Text] [Related]
5. Extent of radiosensitization by the PARP inhibitor olaparib depends on its dose, the radiation dose and the integrity of the homologous recombination pathway of tumor cells.
Verhagen CV; de Haan R; Hageman F; Oostendorp TP; Carli AL; O'Connor MJ; Jonkers J; Verheij M; van den Brekel MW; Vens C
Radiother Oncol; 2015 Sep; 116(3):358-65. PubMed ID: 25981132
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
Gravells P; Neale J; Grant E; Nathubhai A; Smith KM; James DI; Bryant HE
DNA Repair (Amst); 2018 Jan; 61():25-36. PubMed ID: 29179156
[TBL] [Abstract][Full Text] [Related]
7. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
Bi Y; Verginadis II; Dey S; Lin L; Guo L; Zheng Y; Koumenis C
Gynecol Oncol; 2018 Sep; 150(3):534-544. PubMed ID: 30025822
[TBL] [Abstract][Full Text] [Related]
8. Novel poly (ADP-ribose) polymerase inhibitor, AZD2281, enhances radiosensitivity of both normoxic and hypoxic esophageal squamous cancer cells.
Zhan L; Qin Q; Lu J; Liu J; Zhu H; Yang X; Zhang C; Xu L; Liu Z; Cai J; Ma J; Dai S; Tao G; Cheng H; Sun X
Dis Esophagus; 2016 Apr; 29(3):215-23. PubMed ID: 25604309
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia Potentiates the Radiation-Sensitizing Effect of Olaparib in Human Non-Small Cell Lung Cancer Xenografts by Contextual Synthetic Lethality.
Jiang Y; Verbiest T; Devery AM; Bokobza SM; Weber AM; Leszczynska KB; Hammond EM; Ryan AJ
Int J Radiat Oncol Biol Phys; 2016 Jun; 95(2):772-81. PubMed ID: 27020103
[TBL] [Abstract][Full Text] [Related]
10. PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53.
Liu Q; Gheorghiu L; Drumm M; Clayman R; Eidelman A; Wszolek MF; Olumi A; Feldman A; Wang M; Marcar L; Citrin DE; Wu CL; Benes CH; Efstathiou JA; Willers H
Oncogene; 2018 May; 37(21):2793-2805. PubMed ID: 29511347
[TBL] [Abstract][Full Text] [Related]
11. The combination of olaparib and camptothecin for effective radiosensitization.
Miura K; Sakata K; Someya M; Matsumoto Y; Matsumoto H; Takahashi A; Hareyama M
Radiat Oncol; 2012 Apr; 7():62. PubMed ID: 22524618
[TBL] [Abstract][Full Text] [Related]
12. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
Wang W; Duan B; Zeng L
Zhongguo Fei Ai Za Zhi; 2016 Jan; 19(1):16-23. PubMed ID: 26805733
[TBL] [Abstract][Full Text] [Related]
13. Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts.
Laird JH; Lok BH; Ma J; Bell A; de Stanchina E; Poirier JT; Rudin CM
Clin Cancer Res; 2018 Oct; 24(20):5143-5152. PubMed ID: 29945991
[No Abstract] [Full Text] [Related]
14. PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors.
Parsels LA; Karnak D; Parsels JD; Zhang Q; Vélez-Padilla J; Reichert ZR; Wahl DR; Maybaum J; O'Connor MJ; Lawrence TS; Morgan MA
Mol Cancer Res; 2018 Feb; 16(2):222-232. PubMed ID: 29133592
[TBL] [Abstract][Full Text] [Related]
15. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma.
Nile DL; Rae C; Hyndman IJ; Gaze MN; Mairs RJ
BMC Cancer; 2016 Aug; 16():621. PubMed ID: 27515310
[TBL] [Abstract][Full Text] [Related]
16. BLM helicase inhibition synergizes with PARP inhibition to improve the radiosensitivity of olaparib resistant non-small cell lung cancer cells by inhibiting homologous recombination repair.
Kong Y; Xu C; Sun X; Sun H; Zhao X; He N; Ji K; Wang Q; Du L; Wang J; Zhang M; Liu Y; Wang Y; Liu Q
Cancer Biol Med; 2021 Dec; 19(8):1150-71. PubMed ID: 34846107
[TBL] [Abstract][Full Text] [Related]
17. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
Jang NY; Kim DH; Cho BJ; Choi EJ; Lee JS; Wu HG; Chie EK; Kim IA
BMC Cancer; 2015 Mar; 15():89. PubMed ID: 25884663
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
Senra JM; Telfer BA; Cherry KE; McCrudden CM; Hirst DG; O'Connor MJ; Wedge SR; Stratford IJ
Mol Cancer Ther; 2011 Oct; 10(10):1949-58. PubMed ID: 21825006
[TBL] [Abstract][Full Text] [Related]
19. PARP inhibitor olaparib sensitizes esophageal carcinoma cells to fractionated proton irradiation.
Kageyama SI; Junyan D; Hojo H; Motegi A; Nakamura M; Tsuchihara K; Akimoto T
J Radiat Res; 2020 Mar; 61(2):177-186. PubMed ID: 31976528
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option.
Pessetto ZY; Yan Y; Bessho T; Natarajan A
Breast Cancer Res Treat; 2012 Jul; 134(2):511-7. PubMed ID: 22562176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
